Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy. Materials and methods: Out of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments. Results: Among 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%). Conclusion: Response to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients' preference, morbidity, and prognosis.
Abstract
Purpose: Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy. Materials and methods: Out of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments. Results: Among 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%). Conclusion: Response to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients' preference, morbidity, and prognosis.
참고문헌 (23)
- Marur S, "Head and neck squamous cell carcinoma : update on epidemiology, diagnosis, and treatment", Mayo Clin Proc, 91, pp.386~396 (2016)
- Lee YG, "Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma : a nationwide retrospective cohort study(KCSG HN13-01)", BMC Cancer, 20, pp.813~ (2020)
- Pignon JP, "Meta-analysis of chemotherapy in head and neck cancer(MACH-NC) : an update on 93 randomised trials and 17, 346 patients", Radiother Oncol, 92, pp.4~14 (2009)
- Brizel DM, "Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer", Int J Radiat Oncol Biol Phys, 58, pp.1418~1423 (2004)
- Cohen EE, "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer", J Clin Oncol, 32, pp.2735~2743 (2014)
- Zhang L, "Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck : a meta-analysis", Sci Rep, 5, pp.10798~ (2015)
- Haddad RI, "Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck : role, controversy, and future directions", Ann Oncol, 29, pp.1130~1140 (2018)
- Gregoire V, "Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 21(Suppl 5), pp.v184~6 (2010)
- Janoray G, "Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, +", – docetaxel for larynx preservation, 2016, pp.108, djv368~
- 김률, "The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis", Cancer Research and Treatment, 48(3), pp.907~916 (2016), 대한암학회
- Kiong KL, "Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck", Laryngoscope, 128, pp.1594~1601 (2018)
- Ensley JF, "Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck", Cancer, 54, pp.811~814 (1984)
- Hong WK, "Sequential response patterns to chemotherapy and radiotherapy in head and neck cancer : potential impact of treatment in advanced laryngeal cancer", Prog Clin Biol Res, 201, pp.191~197 (1985)
- Department of Veterans Affairs Laryngeal Cancer Study Group, "Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer", N Engl J Med, 324, pp.1685~1690 (1991)
- Lefebvre JL, "Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma : 10-year results of EORTC trial 24891", Ann Oncol, 23, pp.2708~2714 (2012)
- Pointreau Y, "Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation", J Natl Cancer Inst, 101, pp.498~506 (2009)
- Haddad R, "Induction chemotherapy followed by concurrent chemoradiotherapy(sequential chemoradiotherapy)versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer(PARADIGM) : a randomised phase 3 trial", Lancet Oncol, 14, pp.257~264 (2013)
- Geoffrois L, "Induction docetaxel platinum 5-FU(TPF)followed by cetuximab-radiotherapy(cetux-RT)versus concurrent chemo-radiotherapy(CT", RT)in patients with N2b, J Clin Oncol, pp.2016, 34(15 Suppl)[DOI]
- Marur S, "E1308 : phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group", J Clin Oncol, 35, pp.490~497 (2017)
- Ernani V, "Oral cavity cancer : risk factors, pathology, and management", Oncology, 89, pp.187~195 (2015)
- Posner MR, "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer", N Engl J Med, 357, pp.1705~1715 (2007)
- Lorch JH, "Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck : long-term results of the TAX 324 randomised phase 3 trial", Lancet Oncol, 12, pp.153~159 (2011)
- Blanchard P, "Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers : an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group", J Clin Oncol, 31, pp.2854~2860 (2013)
